46 results on '"Shen, Nan"'
Search Results
2. Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis
- Author
-
Ding, Huihua, Shen, Yiwei, Lin, Cheng, Qin, Ling, He, Shijun, Dai, Min, Okitsu, Shinji L., DeMartino, Julie A., Guo, Qiang, and Shen, Nan
- Published
- 2022
- Full Text
- View/download PDF
3. Expanding Roles of Noncoding RNAs in the Pathogenesis of Systemic Lupus Erythematosus
- Author
-
Shen, Yiwei, Qu, Bo, and Shen, Nan
- Published
- 2022
- Full Text
- View/download PDF
4. Three‐Dimensional Chromosomal Landscape Revealing miR‐146a Dysfunctional Enhancer in Lupus and Establishing a CRISPR‐Mediated Approach to Inhibit the Interferon Pathway.
- Author
-
Zhu, Xinyi, Zhang, Yutong, Yin, Zihang, Ye, Zhizhong, Qin, Yuting, Cheng, Zhaorui, Shen, Yiwei, Yin, Zhihua, Ma, Jianyang, Tang, Yuanjia, Ding, Huihua, Guo, Ya, Hou, Guojun, and Shen, Nan
- Subjects
CHROMOSOMES ,THREE-dimensional imaging ,MONONUCLEAR leukocytes ,MICRORNA ,INTERFERONS ,CELLULAR signal transduction ,GENE expression ,DESCRIPTIVE statistics ,CRISPRS ,SYSTEMIC lupus erythematosus ,SEX chromatin ,TRANSCRIPTION factors ,EPIGENOMICS - Abstract
Objective: The diminished expression of microRNA‐146a (miR‐146a) in systemic lupus erythematosus (SLE) contributes to the aberrant activation of the interferon pathway. Despite its significance, the underlying mechanism driving this reduced expression remains elusive. Considering the integral role of enhancers in steering gene expression, our study seeks to pinpoint the SLE‐affected enhancers responsible for modulating miR‐146a expression. Additionally, we aim to elucidate the mechanisms by which these enhancers influence the contribution of miR‐146a to the activation of the interferon pathway. Methods: Circular chromosome conformation capture sequencing and epigenomic profiles were applied to identify candidate enhancers of miR‐146a. CRISPR activation was performed to screen functional enhancers. Differential analysis of chromatin accessibility was used to identify SLE‐dysregulated enhancers, and the mechanism underlying enhancer dysfunction was investigated by analyzing transcription factor binding. The therapeutic value of a lupus‐related enhancer was further evaluated by targeting it in the peripheral blood mononuclear cells (PBMCs) of patients with SLE through a CRISPR activation approach. Results: We identified shared and cell‐specific enhancers of miR‐146a in distinct immune cells. An enhancer 32.5 kb downstream of miR‐146a possesses less accessibility in SLE, and its chromatin openness was negatively correlated with SLE disease activity. Moreover, CCAAT/enhancer binding protein α, a down‐regulated transcription factor in patients with SLE, binds to the 32.5‐kb enhancer and induces the epigenomic change of this locus. Furthermore, CRISPR‐based activation of this enhancer in SLE PBMCs could inhibit the activity of interferon pathway. Conclusion: Our work defines a promising target for SLE intervention. We adopted integrative approaches to define cell‐specific and functional enhancers of the SLE critical gene and investigated the mechanism underlying its dysregulation mediated by a lupus‐related enhancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Anti-Toxoplasma gondii antibodies as a risk factor for the prevalence and severity of systemic lupus erythematosus.
- Author
-
Li, Zhongzhen, Lei, Zhiwei, Yang, Wanying, Jing, Chunxia, Sun, Xiaolin, Yang, Guang, Zhao, Xiaozhen, Zhang, Mingjiao, Xu, Miaomiao, Tang, Yuanjia, Wang, Qingwen, Zhao, Jing, Zhou, Zixing, Wen, Zihao, Chen, Xiaojing, Peng, Qinglin, Wang, Guochun, Zhang, Pingjing, Sun, Erwei, and Shen, Nan
- Subjects
SYSTEMIC lupus erythematosus ,SERUM ,IMMUNOGLOBULIN G ,RHEUMATOID factor ,IMMUNOGLOBULINS ,ENZYME-linked immunosorbent assay ,PHOSPHOLIPID antibodies ,AUTOIMMUNE diseases - Abstract
Background: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease characterized by the presence of numerous autoantibodies. The interaction of infectious agents (viruses, bacteria and parasites) and a genetically susceptible host may be a key mechanism for SLE. Toxoplasma gondii is a widespread intracellular parasite that has been implicated in the pathogenesis of autoimmune diseases. However, the relationship between T. gondii infection and the increased risk of SLE in Chinese populations remains unclear. Methods: The seroprevalence of T. gondii infection was assessed in 1771 serum samples collected from Chinese individuals (908 healthy controls and 863 SLE patients) from different regions of China using an enzyme-linked immunosorbent assay. Serum autoantibodies and clinical information were obtained and analysed. Results: Our observations revealed a higher prevalence of anti-T. gondii antibodies (ATxA) immunoglobulin G (IgG) in serum samples from SLE patients (144/863, 16.7%) than in those from the healthy controls (53/917, 5.8%; P < 0.0001), indicating a 2.48-fold increased risk of SLE in the ATxA-IgG
+ population, after adjustment for age and sex (95% confidence interval [CI] 1.70–3.62, P < 0.0001). ATxA-IgG+ SLE patients also showed a 1.75-fold higher risk of developing moderate and severe lupus symptoms (95% CI 1.14–2.70, P = 0.011) compared to ATxA-IgG− patients. Relative to ATxA-IgG− patients, ATxA-IgG+ patients were more likely to develop specific clinical symptoms, including discoid rash, oral ulcer, myalgia and alopecia. Seven antibodies, namely anti-ribosomal RNA protein (rRNP), anti-double stranded DNA (dsDNA), anti-cell membrane DNA (cmDNA), anti-scleroderma-70 (Scl-70), anti-cardiolipin (CL), anti-beta2-glycoprotein-I (B2GPI) and rheumatoid factor (RF), occurred more frequently in ATxA-IgG+ patients. When combined with anti-dsDNA and RF/anti-rRNP/anti-cmDNA/ESR, ATxA-IgG significantly increased the risk for severe lupus. Conclusions: Our results suggest that ATxA-IgG may be a significant risk factor for SLE prevalence and severity in Chinese populations. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Serum Metabolic Fingerprints Characterize Systemic Lupus Erythematosus.
- Author
-
Li, Shunxiang, Ding, Huihua, Qi, Ziheng, Yang, Jing, Huang, Jingyi, Huang, Lin, Zhang, Mengji, Tang, Yuanjia, Shen, Nan, Qian, Kun, Guo, Qiang, and Wan, Jingjing
- Subjects
SYSTEMIC lupus erythematosus ,METABOLOMIC fingerprinting ,AUTOIMMUNE diseases ,MASS spectrometry ,RHEUMATOID arthritis - Abstract
Metabolic fingerprints in serum characterize diverse diseases for diagnostics and biomarker discovery. The identification of systemic lupus erythematosus (SLE) by serum metabolic fingerprints (SMFs) will facilitate precision medicine in SLE in an early and designed manner. Here, a discovery cohort of 731 individuals including 357 SLE patients and 374 healthy controls (HCs), and a validation cohort of 184 individuals (SLE/HC, 91/93) are constructed. Each SMF is directly recorded by nano‐assisted laser desorption/ionization mass spectrometry (LDI MS) within 1 minute using 1 µL of native serum, which contains 908 mass to charge features. Sparse learning of SMFs achieves the SLE identification with sensitivity/specificity and area‐under‐the‐curve (AUC) up to 86.0%/92.0% and 0.950 for the discovery cohort. For the independent validation cohort, it exhibits no performance loss by affording the sensitivity/specificity and AUC of 89.0%/100.0% and 0.992. Notably, a metabolic biomarker panel is screened out from the SMFs, demonstrating the unique metabolic pattern of SLE patients different from both HCs and rheumatoid arthritis patients. In conclusion, SMFs characterize SLE by revealing its unique metabolic pattern. Different regulation of small molecule metabolites contributes to the precise diagnosis of autoimmune disease and further exploration of the pathogenic mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Biomarkers for systemic lupus erythematosus – a focus on organ damage.
- Author
-
Ding, Huihua, Shen, Yiwei, Hong, Soon-Min, Xiang, Chunyan, and Shen, Nan
- Subjects
SYSTEMIC lupus erythematosus ,BIOMARKERS ,AUTOIMMUNE diseases ,DIAGNOSIS ,INDIVIDUALIZED medicine ,NERVOUS system - Abstract
Systemic lupus erythematosus (SLE) is complex autoimmune disease with heterogenous manifestations, unpredictable disease course and response to treatment. One of the critical needs in SLE management is the identification of reliable biomarkers that can aid in early diagnosis, accurate monitoring of disease activity, and assessment of treatment response. In the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment. The subtitles within each organ domain were determined based on the most relevant and promising biomarkers for that specific organ damage. Biomarkers have the potential to significantly benefit the management of SLE by aiding in diagnosis, disease activity monitoring, prognosis, and treatment response assessment. However, despite decades of research, none has been validated and implemented for routine clinical use. Novel biomarkers could lead to the development of precision medicine for SLE, guide personalized treatment, and improve patient outcomes. Challenges in biomarker research in SLE include defining clear and clinically relevant questions, accounting for the heterogeneity of SLE, and confirming initial findings in larger, multi-center, multi-ethnic, independent cohorts that reflect real-world clinical scenarios. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients
- Author
-
Liu, Mei, Guo, Qiang, Wu, Chunmei, Sterlin, Delphine, Goswami, Shyamal, Zhang, Ying, Li, Teng, Bao, Chunde, Shen, Nan, Fu, Qiong, and Zhang, Xiaoming
- Published
- 2019
- Full Text
- View/download PDF
9. MicroRNAs in Systemic Lupus Erythematosus: a Perspective on the Path from Biological Discoveries to Clinical Practice
- Author
-
Hong, Soon-Min, Liu, Can, Yin, Zhihua, Wu, Lingling, Qu, Bo, and Shen, Nan
- Published
- 2020
- Full Text
- View/download PDF
10. Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants.
- Author
-
Vinuesa, Carola G., Shen, Nan, and Ware, Thuvaraka
- Subjects
- *
B cell receptors , *GENETICS , *SYSTEMIC lupus erythematosus , *TYPE I interferons , *NUCLEIC acids , *B cells - Abstract
The past few years have provided important insights into the genetic architecture of systemic autoimmunity through aggregation of findings from genome-wide association studies (GWAS) and whole-exome or whole-genome sequencing studies. In the prototypic systemic autoimmune disease systemic lupus erythematosus (SLE), monogenic disease accounts for a small fraction of cases but has been instrumental in the elucidation of disease mechanisms. Defects in the clearance or digestion of extracellular or intracellular DNA or RNA lead to increased sensing of nucleic acids, which can break B cell tolerance and induce the production of type I interferons leading to tissue damage. Current data suggest that multiple GWAS SLE risk alleles act in concert with rare functional variants to promote SLE development. Moreover, introduction of orthologous variant alleles into mice has revealed that pathogenic X-linked dominant and recessive SLE can be caused by novel variants in TLR7 and SAT1, respectively. Such bespoke models of disease help to unravel pathogenic pathways and can be used to test targeted therapies. Cell type-specific expression data revealed that most GWAS SLE risk genes are highly expressed in age-associated B cells (ABCs), which supports the view that ABCs produce lupus autoantibodies and contribute to end-organ damage by persisting in inflamed tissues, including the kidneys. ABCs have thus emerged as key targets of promising precision therapeutics. This Review examines insights from genetic studies of systemic lupus erythematosus (SLE), including observations from reports of monogenic SLE, as well as the role of common and rare variants. The authors also discuss age-associated B cells, as the integration of genetic, epigenetic and transcriptomic data suggests a key role for these cells in SLE. Key points: Monogenic systemic lupus erythematosus (SLE) commonly results from defects in degradation or increased sensing of nucleic acids and have led to the development of in vivo models of disease and mechanistic exploration of pathogenesis. The study of high frequency and variably penetrant common variants must be integrated with the study of low frequency, highly penetrant rare, ultra-rare and novel variants to clarify the genetic contribution to disease. Common variants identified through genome-wide association studies (GWAS) highlight a role for complement, immune complex handling, endosomal Toll-like receptors, type I interferon signalling, B cell tolerance and B cell receptor signalling pathways in SLE. The use of online transcriptomic databases to integrate GWAS data highlighted an increased expression of SLE-associated genes in age-associated B cells (ABCs). ABCs are expanded peripherally in patients with SLE, especially in those with lupus nephritis, and in the kidney during episodes of lupus nephritis. Therapeutic regimens that target CD19+ B cells are highly effective at depletion of ABCs, which express high levels of CD19, and had a promising effect in a small study of patients with refractory SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. The Oxysterol Receptor EBI2 Links Innate and Adaptive Immunity to Limit IFN Response and Systemic Lupus Erythematosus.
- Author
-
Zhang, Fang, Zhang, Baokai, Ding, Huihua, Li, Xiangyue, Wang, Xilin, Zhang, Xiaomin, Liu, Qiaojie, Feng, Qiuyun, Han, Mingshun, Chen, Longlong, Qi, Linlin, Yang, Dan, Li, Xiaojing, Zhu, Xingguo, Zhao, Qi, Qiu, Jiaqian, Zhu, Zhengjiang, Tang, Huiru, Shen, Nan, and Wang, Hongyan
- Subjects
SYSTEMIC lupus erythematosus ,NATURAL immunity ,B cells ,TYPE I interferons ,CHEMOKINE receptors ,IMMUNE system ,CELL migration - Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with abnormal activation of the immune system. Recent attention is increasing about how aberrant lipid and cholesterol metabolism is linked together with type I interferon (IFN‐I) signaling in the regulation of the pathogenesis of SLE. Here, a metabonomic analysis is performed and increased plasma concentrations of oxysterols, especially 7α, 25‐dihydroxycholesterol (7α, 25‐OHC), are identified in SLE patients. The authors find that 7α, 25‐OHC binding to its receptor Epstein–Barr virus‐induced gene 2 (EBI2) in macrophages can suppress STAT activation and the production of IFN‐β, chemokines, and cytokines. Importantly, monocytes/macrophages from SLE patients and mice show significantly reduced EBI2 expression, which can be triggered by IFN‐γ produced in activated T cells. Previous findings suggest that EBI2 enhances immune cell migration. Opposite to this effect, the authors demonstrate that EBI2‐deficient macrophages produce higher levels of chemokines and cytokines, which recruits and activates myeloid cells,T and B lymphocytes to exacerbate tetramethylpentadecane‐induced SLE. Together, via sensing the oxysterol 7α, 25‐OHC, EBI2 in macrophages can modulate innate and adaptive immune responses, which may be used as a potential diagnostic marker and therapeutic target for SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Involvement of Transcriptional Factor Pbx1 in Peripheral B Cell Homeostasis to Constrain Lupus Autoimmunity.
- Author
-
Gu, Shuangshuang, Zhang, Jinsong, Han, Xiaxia, Ding, Huihua, Yao, Chao, Ye, Zhizhong, Yin, Zhihua, Hou, Guojun, Jiang, Yang, Qian, Jie, Zhou, Haibo, Guo, Qiang, Chen, Sheng, Dai, Dai, and Shen, Nan
- Subjects
HOMEOSTASIS ,CELL differentiation ,IMMUNIZATION ,SEQUENCE analysis ,ANIMAL experimentation ,INTRAPERITONEAL injections ,RNA ,PRECIPITIN tests ,RESEARCH funding ,TRANSCRIPTION factors ,POLYMERASE chain reaction ,SYSTEMIC lupus erythematosus ,MICE - Abstract
Objective: Disruption of B cell homeostasis and subsequent dominance of effector B cell subsets are critical for the development of systemic lupus erythematosus (SLE). Revealing the key intrinsic regulators involved in the homeostatic control of B cells has important therapeutic value for SLE. This study was undertaken to determine the regulatory role of the transcription factor Pbx1 in B cell homeostasis and lupus pathogenesis. Methods: We constructed mice with B cell–specific deletion of Pbx1. T cell–dependent and T cell–independent humoral responses were induced by intraperitoneal injection of nitrophenyl‐containing hapten (NP) conjugated to keyhole limpet hemocyanin or NP‐Ficoll. The regulatory effects of Pbx1 on autoimmunity were observed in a Bm12‐induced lupus murine model. We investigated mechanisms of Pbx1 using RNA sequencing, the cleavage under targets and tagmentation assay, and chromatin immunoprecipitation–quantitative polymerase chain reaction assay. We transduced B cells from SLE patients with plasmids that overexpressed PBX1 to explore the in vitro therapeutic efficacy of PBX1. Results: Pbx1 was specifically down‐regulated in autoimmune B cells and negatively correlated with disease activity. The deficiency of Pbx1 in B cells resulted in excessive humoral responses following immunization. In the Bm12‐induced lupus model, mice with B cell–specific Pbx1 deficiency displayed enhancements in germinal center responses, plasma cell differentiation, and autoantibody production. Pbx1‐deficient B cells had increased survival and proliferative advantages after activation. Pbx1 regulated genetic programs by directly targeting critical components of the proliferation and apoptosis pathways. In SLE patients, PBX1 expression was negatively correlated with effector B cell expansion; when PBX1 expression was enforced, the survival and proliferative capacity of SLE B cells were attenuated. Conclusion: Our study reveals the regulatory function and mechanism of Pbx1 in adjusting B cell homeostasis and highlights Pbx1 as a therapeutic target in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Amelioration of Autoimmunity in a Lupus Mouse Model by Modulation of T‐Bet–Promoted Energy Metabolism in Pathogenic Age/Autoimmune‐Associated B Cells.
- Author
-
Han, Xiaxia, Gu, Shuangshuang, Hong, Soon‐Min, Jiang, Yang, Zhang, Jinsong, Yao, Chao, Yin, Zhihua, Ye, Zhizhong, Ding, Huihua, Chen, Sheng, Dai, Dai, and Shen, Nan
- Subjects
PROTEIN metabolism ,BIOLOGICAL models ,ENERGY metabolism ,AUTOANTIBODIES ,B cells ,ANIMAL experimentation ,RNA ,INTERFERONS ,IMMUNITY ,SYSTEMIC lupus erythematosus ,MICE ,GLYCOLYSIS - Abstract
Objective: Emerging evidence indicates that a distinct CD11c+T‐bet+ B cell subset, termed age/autoimmune‐associated B cells (ABCs), is the major pathogenic autoantibody producer in lupus. Human lupus is associated with significant metabolic alterations, but how ABCs orchestrate their typical transcription factors and metabolic programs to meet specific functional requirements is unclear. We undertook this study to characterize the metabolism of ABCs and to identify the regulators of their metabolic pathways in an effort to develop new therapies for ABC‐mediated autoimmunity. Methods: We developed a T‐bet–tdTomato reporter mouse strain to trace live T‐bet+ B cells and adoptively transferred CD4+ T cells from bm12 mice to induce lupus. We next sorted CD11c+tdTomato+ B cells and conducted RNA sequencing and an extracellular flux assay. A metabolic restriction to constrain ABC formation was tested in human and mouse B cells. We used a bm12‐induced lupus mouse model to conduct the metabolic intervention. Results: ABCs exhibited a hypermetabolic state with enhanced glycolytic capacity. The increased glycolytic rate in ABCs was promoted by interferon‐γ (IFNγ) signaling. T‐bet, a downstream transcription factor of IFNγ, regulated the gene program of the glycolysis pathway in ABCs by repressing the expression of Bcl6. Functionally, glycolysis restriction could impair ABC formation. The engagement of glycolysis promoted survival and terminal differentiation of antibody‐secreting cells. Administration of a glycolysis inhibitor ameliorated ABC accumulation and autoantibody production in the lupus‐induced bm12 mouse model. Conclusion: T‐bet can couple immune signals and metabolic programming to establish pathogenic ABC formation and functional capacities. Modulation of ABCs favored a metabolic program that could be a novel therapeutic approach for lupus. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Lupus nephritis or not? A simple and clinically friendly machine learning pipeline to help diagnosis of lupus nephritis.
- Author
-
Wang, Da-Cheng, Xu, Wang-Dong, Wang, Shen-Nan, Wang, Xiang, Leng, Wei, Fu, Lu, Liu, Xiao-Yan, Qin, Zhen, and Huang, An-Fang
- Subjects
MACHINE learning ,LUPUS nephritis ,FEATURE selection ,SYSTEMIC lupus erythematosus ,SUPPORT vector machines ,RANDOM forest algorithms - Abstract
Objective: Diagnosis of lupus nephritis (LN) is a complex process, which usually requires renal biopsy. We aim to establish a machine learning pipeline to help diagnosis of LN. Methods: A cohort of 681 systemic lupus erythematosus (SLE) patients without LN and 786 SLE patients with LN was established, and a total of 95 clinical, laboratory data and 17 meteorological indicators were collected. After tenfold cross-validation, the patients were divided into training set and test set. The features selected by collective feature selection method of mutual information (MI) and multisurf were used to construct the models of logistic regression, decision tree, random forest, naive Bayes, support vector machine (SVM), light gradient boosting (LGB), extreme gradient boosting (XGB), and artificial neural network (ANN), the models were compared and verified in post-analysis. Results: Collective feature selection method screens out antistreptolysin (ASO), retinol binding protein (RBP), lupus anticoagulant 1 (LA1), LA2, proteinuria and other features, and the hyperparameter optimized XGB (ROC: AUC = 0.995; PRC: AUC = 1.000, APS = 1.000; balance accuracy: 0.990) has the best performance, followed by LGB (ROC: AUC = 0.992; PRC: AUC = 0.997, APS = 0.977; balance accuracy: 0.957). The worst performance is naive Bayes model (ROC: AUC = 0.799; PRC: AUC = 0.822, APS = 0.823; balance accuracy: 0.693). In the composite feature importance bar plots, ASO, RF, Up/Ucr, and other features play important roles in LN. Conclusion: We developed and validated a new and simple machine learning pathway for diagnosis of LN, especially the XGB model based on ASO, LA1, LA2, proteinuria, and other features screened out by collective feature selection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. De Novo PACSIN1 Gene Variant Found in Childhood Lupus and a Role for PACSIN1/TRAF4 Complex in Toll‐like Receptor 7 Activation.
- Author
-
Xie, Chengmei, Zhou, Haibo, Athanasopoulos, Vicki, Shen, Qian, Zhang, Yaoyuan, Meng, Xiangpeng, Burgio, Gaetan, Arsov, Todor, Lungu, Adrian C., Zhang, Pingjing, Qin, Yuting, Ma, Jiangyang, Wu, Xiaoqian, Jiang, Xiaoyue, Ding, Huihua, Meng, Yao, Shen, Nan, He, Yuke, and Vinuesa, Carola G.
- Subjects
SYSTEMIC lupus erythematosus diagnosis ,FLOW cytometry ,ANIMAL experimentation ,RNA ,GENES ,DESCRIPTIVE statistics ,SYSTEMIC lupus erythematosus ,CELL lines ,POLYMERASE chain reaction ,TOLL-like receptors ,MICE ,CHILDREN - Abstract
Objective: Increased Toll‐like receptor 7 (TLR‐7) signaling leading to the production of type I interferon (IFN) is an important contributor to human systemic lupus erythematosus (SLE). Protein kinase C and casein kinase substrate in neurons 1 (PACSIN1), a molecule that regulates synaptic vesicle recycling, has been linked to TLR‐7/TLR‐9–mediated type I IFN production in humans and mice, but the underlying mechanism is unknown. We undertook this study to explore the pathogenicity and underlying mechanism of a de novo PACSIN1 missense variant identified in a child with SLE. Methods: PACSIN1 Q59K de novo and null variants were introduced into a human plasmacytoid dendritic cell line and into mice using CRISPR/Cas9 editing. The effects of the variants on TLR‐7/TLR‐9 signaling in human and mouse cells, as well as PACSIN1 messenger RNA and IFN signature in SLE patients, were assessed using real‐time polymerase chain reaction and flow cytometry. Mechanisms were investigated using luciferase reporter assays, RNA interference, coimmunoprecipitation, and immunofluorescence. Results: We established that PACSIN1 forms a trimolecular complex with tumor necrosis factor receptor–associated factor 4 (TRAF4) and TRAF6 that is important for the regulation of type I IFN. The Q59K mutation in PACSIN1 augments binding to neural Wiskott‐Aldrich syndrome protein while it decreases binding to TRAF4, leading to unrestrained TRAF6‐mediated activation of type I IFN. Intriguingly, PACSIN1 Q59K increased TLR‐7 but not TLR‐9 signaling in human cells, leading to elevated expression of IFNβ and IFN‐inducible genes. Untreated SLE patients had high PACSIN1 expression in peripheral blood cells that correlated positively with IFN‐related genes. Introduction of the Pacsin1 Q59K mutation into mice caused increased surface TLR‐7 and TRAIL expression in B cells. Conclusion: PACSIN1 Q59K increases IFNβ activity through the impairment of TRAF4‐mediated inhibition of TLR‐7 signaling, possibly contributing to SLE risk. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry.
- Author
-
Owen, Katherine A., Bell, Kristy A., Price, Andrew, Bachali, Prathyusha, Ainsworth, Hannah, Marion, Miranda C., Howard, Timothy D., Langefeld, Carl D., Shen, Nan, Yazdany, Jinoos, Dall'era, Maria, Grammer, Amrie C., and Lipsky, Peter E.
- Subjects
SINGLE nucleotide polymorphisms ,SYSTEMIC lupus erythematosus ,GENE expression ,GENE mapping ,GENOME-wide association studies ,GENE expression profiling - Abstract
Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disorder with a prominent genetic component. Individuals of Asian-Ancestry (AsA) disproportionately experience more severe SLE compared to individuals of European-Ancestry (EA), including increased renal involvement and tissue damage. However, the mechanisms underlying elevated severity in the AsA population remain unclear. Here, we utilized available gene expression data and genotype data based on all non-HLA SNP associations in EA and AsA SLE patients detected using the Immunochip genotyping array. We identified 2778 ancestry-specific and 327 trans-ancestry SLE-risk polymorphisms. Genetic associations were examined using connectivity mapping and gene signatures based on predicted biological pathways and were used to interrogate gene expression datasets. SLE-associated pathways in AsA patients included elevated oxidative stress, altered metabolism and mitochondrial dysfunction, whereas SLE-associated pathways in EA patients included a robust interferon response (type I and II) related to enhanced cytosolic nucleic acid sensing and signaling. An independent dataset derived from summary genome-wide association data in an AsA cohort was interrogated and identified similar molecular pathways. Finally, gene expression data from AsA SLE patients corroborated the molecular pathways predicted by SNP associations. Identifying ancestry-related molecular pathways predicted by genetic SLE risk may help to disentangle the population differences in clinical severity that impact AsA and EA individuals with SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus.
- Author
-
Hou, Guojun, Zhou, Tian, Xu, Ning, Yin, Zhihua, Zhu, Xinyi, Zhang, Yutong, Cui, Yange, Ma, Jianyang, Tang, Yuanjia, Cheng, Zhaorui, Shen, Yiwei, Chen, Yashuo, Zou, Ling‐Hua, Wang, Yong‐fei, Yin, Zihang, Guo, Ya, Ding, Huihua, Ye, Zhizhong, and Shen, Nan
- Subjects
PROTEINS ,SINGLE nucleotide polymorphisms ,FORMALDEHYDE ,GENETIC variation ,GENETIC testing ,QUANTITATIVE research ,ALLELES ,PRECIPITIN tests ,GENE expression ,RISK assessment ,GENOME-wide association studies ,GENOMICS ,SYSTEMIC lupus erythematosus ,POLYMERASE chain reaction ,EPIGENOMICS ,DISEASE risk factors - Abstract
Objective: IRF5 plays a crucial role in the development of lupus. Genome‐wide association studies have identified several systemic lupus erythematosus (SLE) risk single‐nucleotide polymorphisms (SNPs) enriched in the IRF5 locus. However, no comprehensive genome editing–based functional analysis exists to establish a direct link between these variants and altered IRF5 expression, particularly for enhancer variants. This study was undertaken to dissect the regulatory function and mechanisms of SLE IRF5 enhancer risk variants and to explore the utilization of clustered regularly interspaced short palindromic repeat interference (CRISPRi) to regulate the expression of disease risk gene to intervene in the disease. Methods: Epigenomic profiles and expression quantitative trait locus analysis were applied to prioritize putative functional variants in the IRF5 locus. CRISPR‐mediated deletion, activation, and interference were performed to investigate the genetic function of rs4728142. Allele‐specific chromatin immunoprecipitation–quantitative polymerase chain reaction and allele‐specific formaldehyde‐assisted isolation of regulatory element–quantitative polymerase chain reaction were used to decipher the mechanism of alleles differentially regulating IRF5 expression. The CRISPRi approach was used to evaluate the intervention effect in monocytes from SLE patients. Results: SLE risk SNP rs4728142 was located in an enhancer region, indicating a disease‐related regulatory function, and risk allele rs4728142‐A was closely associated with increased IRF5 expression. We demonstrated that an rs4728142‐containing region could act as an enhancer to regulate the expression of IRF5. Moreover, rs4728142 affected the binding affinity of zinc finger and BTB domain–containing protein 3 (ZBTB3), a transcription factor involved in regulation. Furthermore, in monocytes from SLE patients, CRISPR‐based interference with the regulation of this enhancer attenuated the production of disease‐associated cytokines. Conclusion: These results demonstrate that the rs4728142‐A allele increases the SLE risk by affecting ZBTB3 binding, chromatin status, and regulating IRF5 expression, establishing a biologic link between genetic variation and lupus pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus
- Author
-
Shen, Nan, Fu, Qiong, Deng, Yun, Qian, Xiaoxia, Zhao, Jian, Kaufman, Kenneth M., Wu, Yee Ling, Yu, C. Yung, Tang, Yuanjia, Chen, Ji-Yih, Yang, Wanling, Wong, Maida, Kawasaki, Aya, Tsuchiya, Naoyuki, Sumida, Takayuki, Kawaguchi, Yasushi, Howe, Hwee Siew, Mok, Mo Yin, Bang, So-Young, Liu, Fei-Lan, Chang, Deh-Ming, Takasaki, Yoshinari, Hashimoto, Hiroshi, Harley, John B., Guthridge, Joel M., Grossman, Jennifer M., Cantor, Rita M., Song, Yeong Wook, Bae, Sang-Cheol, Chen, Shunle, Hahn, Bevra H., Lau, Yu Lung, Tsao, Betty P., and Smith, Kenneth G. C.
- Published
- 2010
19. Association of a Common Complement Receptor 2 Haplotype with Increased Risk of Systemic Lupus Erythematosus
- Author
-
Wu, Hui, Boackle, Susan A., Hanvivadhanakul, Punchong, Ulgiati, Daniela, Grossman, Jennifer M., Lee, Youngho, Shen, Nan, Abraham, Lawrence J., Mercer, Timothy R., Park, Elly, Hebert, Lee A., Rovin, Brad H., Birmingham, Dan J., Chang, Deh-Ming, Chen, Chung Jen, McCurdy, Deborah, Badsha, Humeira M., Thong, Bernard Y. H., Chng, Hiok H., Arnett, Frank C., Wallace, Daniel J., Yu, C. Yung, Hahn, Bevra H., Cantor, Rita M., and Tsao, Betty P.
- Published
- 2007
- Full Text
- View/download PDF
20. Chest imaging manifestations in lupus nephritis
- Author
-
Qin, Hui, Guo, Qiang, Shen, Nan, Huang, Xinfang, Wu, Huawei, Zhang, Minfang, Bao, Chunde, and Chen, Shunle
- Published
- 2014
- Full Text
- View/download PDF
21. AKT2 reduces IFNβ1 production to modulate antiviral responses and systemic lupus erythematosus.
- Author
-
Zheng, Xin, Xiao, Jun, Jiang, Qi, Zheng, Lingming, Liu, Chang, Dong, Chen, Zheng, Yuxiao, Ni, Peili, Zhang, Chi, Zhang, Fang, Zhong, Ruiyue, Ding, Huihua, Wang, Qiong, Qiu, Ying, Gao, Minxia, Ding, Jianping, Shen, Nan, Wei, Bin, and Wang, Hongyan
- Subjects
SYSTEMIC lupus erythematosus ,TYPE I interferons ,INTERFERON regulatory factors ,VIRUS diseases ,LABORATORY mice ,PROTEIN kinases - Abstract
Interferon regulatory factor 3 (IRF3)‐induced type I interferon (I‐IFN) production plays key roles in both antiviral and autoimmune responses. IRF3 phosphorylation, dimerization, and nuclear localization are needed for its activation and function, but the precise regulatory mechanisms remain to be explored. Here, we show that the serine/threonine kinase AKT2 interacts with IRF3 and phosphorylates it on Thr207, thereby attenuating IRF3 nuclear translocation in a 14‐3‐3ε‐dependent manner and reducing I‐IFN production. We further find that AKT2 expression is downregulated in viral‐infected macrophages or in monocytes and tissue samples from systemic lupus erythematosus (SLE) patients and mouse models. Akt2‐deficient mice exhibit increased I‐IFN induction and reduced mortality in response to viral infection, but aggravated severity of SLE. Overexpression of AKT2 kinase‐inactive or IRF3‐T207A mutants in zebrafish supports that AKT2 negatively regulates I‐IFN production and antiviral response in a kinase‐dependent manner. This negative role of AKT2 in IRF3‐induced I‐IFN production suggests that AKT2 may be therapeutically targeted to differentially regulate antiviral infection and SLE. Synopsis: Interferon regulatory factor 3 (IRF3)‐induced type I interferon (I‐IFN) production plays key roles during antiviral response and systemic lupus erythematosus (SLE). Here, AKT2 is shown to regulate I‐IFN production by binding to and phosphorylating IRF3 to attenuate IRF3 nuclear translocation, leading to reduced I‐IFN production. AKT2 expression is downregulated in viral‐infected macrophages and in samples from SLE patients and mouse models.I‐IFN stimulation reduces Akt2 transcription and AKT2 inhibits I‐IFN production.AKT2 binds and phosphorylates IRF3 at Thr207 to reduce IRF3 nuclear localization.Akt2 deficiency promotes IFNβ1 production to favor antiviral response while enhancing SLE in mouse models. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients
- Author
-
Huang, Xinfang, Hua, Jing, Shen, Nan, and Chen, Shunle
- Published
- 2007
- Full Text
- View/download PDF
23. Downregulation of Renal Hsa-miR-127-3p Contributes to the Overactivation of Type I Interferon Signaling Pathway in the Kidney of Lupus Nephritis.
- Author
-
Wu, Lingling, Han, Xiao, Jiang, Xiaoyue, Ding, Huihua, Qi, Chaojun, Yin, Zhihua, Xiao, Jianwei, Xiong, Le, Guo, Qiang, Ye, Zhizhong, Qu, Bo, and Shen, Nan
- Subjects
TYPE I interferons ,CELLULAR signal transduction ,AUTOIMMUNE diseases ,LUPUS nephritis ,SYSTEMIC lupus erythematosus ,DOWNREGULATION ,KIDNEYS - Abstract
MicroRNAs are involved in the pathogenesis of systemic lupus erythematosus (SLE) and dysregulated in the kidneys of lupus nephritis (LN) patients, but their pathogenic roles in LN are largely unknown. Janus Kinase 1 (JAK1) mediates the activation of the downstream signaling pathways of many inflammatory cytokines, including type I interferon (IFN-I) signaling pathway which is critical to the development of SLE and LN. Thus, JAK1 is a potent therapeutic target for these autoimmune diseases. However, there are few studies demonstrating the dysregulation of JAK1 in autoimmune diseases and the molecular mechanism behind it. In this concise report, we show an inhibitory effect of hsa-miR-127-3p, a microRNA that is downregulated in the renal tissues of LN patients, on IFN-I signaling. We found the overexpression of hsa-miR-127-3p could inhibit the induction of ISRE and GAS mediated gene expression, the phosphorylation of STAT1 and STAT2, and the upregulation of IFN stimulated genes (ISGs) stimulated by IFN-I. While, hsa-miR-127-3p antagonist enhanced the activation of IFN-I signaling in primary renal mesangial cells. Subsequently, we identified JAK1 as a bona fide target gene of hsa-miR-127-3p and showed hsa-miR-127-3p targeted JAK1 through binding to its 3'UTR and coding region. Consistently, we found the downregulation of hsa-miR-127-3p was associated with the upregulation of JAK1 and ISGs in kidney tissues of LN patients. Our data indicate renal downregulation of hsa-miR-127-3p contributes to the overactivation of IFN-I signaling pathway in the kidneys of LN patients through promoting the expression of JAK1, suggesting hsa-miR-127-3p mimics may be used to inhibit JAK1 and IFN-I signaling pathway in LN. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus.
- Author
-
Liang, Kaili, He, Jing, Wei, Yunbo, Zeng, Qunxiong, Gong, Dongcheng, Qin, Jiahuan, Ding, Huihua, Chen, Zhian, Zhou, Ping, Niu, Peng, Chen, Qian, Ding, Chenguang, Lu, Liangjing, Chen, Xiao‐Xiang, Li, Zhanguo, Shen, Nan, Yu, Di, and Deng, Jun
- Subjects
HUMORAL immunity ,SYSTEMIC lupus erythematosus ,INTERLEUKIN-2 ,KIDNEY physiology ,IMMUNOFLUORESCENCE ,SPLEEN - Abstract
Objectives: Low‐dose interleukin‐2 (IL‐2) has shown promising clinical benefits in the treatment of systemic lupus erythematosus (SLE), but how this therapy alleviates pathogenic humoral immunity remains not well understood. The dilemma is that IL‐2 can suppress both follicular helper and regulatory T (Tfh and Tfr) cells, which counteract each other in regulating autoantibody production. Methods: Female NZB/W F1 mice received recombinant human IL‐2 (3 × 104 IU/dose) in three treatment regimens: (1) short, daily for 7 days; (2) medium, daily for 14 days, and (3) long, every second day for 28 days. Tfh (Foxp3−CXCR5+Bcl6+), Tfr (Foxp3+CXCR5+Bcl6+), germinal centre (GC, B220+GL‐7+Fas+) and antibody‐secreting cell (ASC, B220−CD138+TACI+) were analysed by flow cytometry. Serum anti‐dsDNA level was determined by ELISA. Kidney pathology was evaluated by H&E and immunofluorescence staining. Circulating Tfh and Tfr cells in SLE patients treated with low‐dose IL‐2 from a previous clinical trial (NCT02084238) was analysed. Results: Low‐dose IL‐2 treatment consistently increased Tfr/Tfh ratio in mice and SLE patients, because of a stronger suppression on Tfh cells than Tfr cells. Three treatment regimens revealed distinct immunological features. Tfh suppression was observed in all regimens, but Tfr suppression and GC reduction were recorded in just medium and long regimens. Only the long treatment regimen resulted in inhibited ASC differentiation in spleen, which was accompanied by reduced anti‐dsDNA titres and ameliorated kidney pathology. Conclusion: Low‐dose IL‐2 therapy increases the Tfr/Tfh ratio, and a less frequent and prolonged treatment can alleviate pathogenic humoral immunity and improve renal function. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Long non-coding RNA expression profiles in neutrophils revealed potential biomarker for prediction of renal involvement in SLE patients.
- Author
-
Cai, Bin, Cai, Jingyi, Yin, Zhihua, Jiang, Xiaoyue, Yao, Chao, Ma, Jianyang, Xue, Zhixin, Miao, Ping, Xiao, Qingqing, Cheng, Yijun, Qin, Jialin, Guo, Qiang, Shen, Nan, Ye, Zhizhong, Qu, Bo, and Ding, Huihua
- Subjects
RNA analysis ,BIOMARKERS ,KRUSKAL-Wallis Test ,KIDNEYS ,LUPUS nephritis ,MANN Whitney U Test ,NEUTROPHILS ,BIOINFORMATICS ,GENE expression profiling ,DESCRIPTIVE statistics ,RESEARCH funding ,SYSTEMIC lupus erythematosus ,POLYMERASE chain reaction - Abstract
Objective The long non-coding RNA plays an important role in inflammation and autoimmune diseases. The aim of this study is to screen and identify abnormally expressed lncRNAs in peripheral blood neutrophils of SLE patients as novel biomarkers and to explore the relationship between lncRNAs levels and clinical features, disease activity and organ damage. Methods RNA-seq technology was used to screen differentially expressed lncRNAs in neutrophils from SLE patients and healthy donors. Based on the results of screening, candidate lncRNA levels in neutrophils of 88 SLE patients, 35 other connective disease controls, and 78 healthy controls were qualified by real-time quantitative polymerase chain reaction. Results LncRNA expression profiling revealed 360 up-regulated lncRNAs and 224 down-regulated lncRNAs in neutrophils of SLE patients when compared with healthy controls. qPCR assay validated that the expression of Lnc-FOSB-1:1 was significantly decreased in neutrophils of SLE patients when compared with other CTD patients or healthy controls. It correlated negatively with SLE Disease Activity Index 2000 (SLEDAI-2K) score (r = −0.541, P < 0.001) and IFN scores (r = −0.337, P = 0.001). More importantly, decreased Lnc-FOSB-1:1 expression was associated with lupus nephritis. Lower baseline Lnc-FOSB-1:1 level was associated with higher risk of future renal involvement (within an average of 2.6 years) in patients without renal disease at baseline (P = 0.019). Conclusion LncRNA expression profile in neutrophils of SLE patients revealed differentially expressed lncRNAs. Validation study on Lnc-FOSB-1:1 suggest that it is a potential biomarker for prediction of near future renal involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. The enrichment of neutrophil extracellular traps impair the placentas of systemic lupus erythematosus through accumulating decidual NK cells.
- Author
-
Jiang, Meng, Shen, Nan, Zhou, Haibo, Wang, You, Lin, Sihan, Wu, Jiayue, and Di, Wen
- Subjects
- *
NEUTROPHILS , *PLACENTA , *SYSTEMIC lupus erythematosus , *KILLER cells , *PREGNANCY complications - Abstract
Despite the advances made in the management of pregnancies in women with systemic lupus erythematosus (SLE), the rate of adverse pregnancy outcomes is still higher than that in the general population. In the last few years, neutrophil extracellular traps (NETs) were proven to be detrimental in both autoimmune diseases and placental injury. We investigated whether NETs could be detected in the placentas of pregnant individuals with SLE and explored the relationship between NETs and decidual natural killer cells (dNKs), which comprise the majority of immune cells at the maternal–fetal interface, using clinical samples and animal models. In this study, we found that the infiltration of NETs and dNKs, especially CD56+CD16+ NK cells, was significantly increased in pregnant individuals with SLE with placental insufficiency. In the murine models of SLE, the number of dNKs was significantly decreased due to the decreased formation of NETs affected by Ly6G. Moreover, the histopathological placental injury was reduced, with a remarkable increase in fetal birth weight. This study shows that NETs may contribute to immunological disorder in the placenta and the pathological changes in pregnancies with SLE, which provides a research basis for further explorations of the mechanism of SLE in placental impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
- Author
-
Wu, Lingling, Jiang, Xiaoyue, Qi, Chaojun, Zhang, Chunyan, Qu, Bo, and Shen, Nan
- Subjects
TYPE I interferons ,MONONUCLEAR leukocytes ,LUPUS nephritis ,SYSTEMIC lupus erythematosus ,INTERFERON beta 1b ,DNA methyltransferases ,INTRAVENOUS injections - Abstract
Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase mediating trimethylation of H3K27, which represses gene expression and is critical to immune regulation. Inhibition of EZH2 is proved to have the potential of treating many diseases. However, whether inhibition of EZH2 affects type I interferon (IFN-I) signaling pathway, the abnormality of which is an important pathogenic mechanism for SLE, is still elusive. Here, we report, unexpectedly, a positive regulatory function of EZH2 in IFN-I signaling pathway, which contributes to the overactivation of IFN-I signaling pathway in SLE. We show that the expression of EZH2 was upregulated and positively correlated with the overexpression of interferon stimulated genes (ISGs) in both peripheral blood mononuclear cells and renal tissues of SLE patients. In vitro inhibition of EZH2 by either siRNAs or chemical inhibitors reduced the phosphorylation of STAT1 and the induction of ISGs stimulated by IFN-I. Additionally, inhibition of EZH2 interfered with the in vivo and ex vivo activation of IFN-I signaling pathway elicited by intravenous injection of adenovirus vector expressing mouse IFN-α5 and exogeneous stimulation with IFN-α, respectively. We evaluated the therapeutic effects of EZH2 inhibitor in NZB/NZW F1 mice which depend on IFN-I signaling pathway for the lupus-like disease development. Administration of EZH2 inhibitor prolonged the survival, reduced the levels of anti-dsDNA autoantibodies, and improved lupus nephritis of the mice. What's more, EZH2 inhibitor attenuated the expression of ISGs in the kidneys of these mice. In summary, we show that excessive EZH2 contributes to the overactivation of IFN-I signaling pathway in SLE. EZH2 inhibitor has the potential to inhibit IFN-I signaling pathway and alleviate lupus nephritis. Additionally, diverse disease driving pathways exist among systemic lupus erythematosus (SLE) patient, and even in the same patients. Common regulators of different pathogenic pathways can be multivalent therapeutic targets. Together with previous studies showing EZH2 is involved in T-cell and B-cell mediated immune responses, EZH2 could be a potent multivalent therapeutic target for SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Taurine Metabolism Aggravates the Progression of Lupus by Promoting the Function of Plasmacytoid Dendritic Cells.
- Author
-
Li, Jun, Ding, Huihua, Meng, Yao, Li, Guanhua, Fu, Qiong, Guo, Qiang, Yin, Zhihua, Ye, Zhizhong, Zhou, Haibo, and Shen, Nan
- Subjects
AMINO acid analysis ,REACTIVE oxygen species ,ALKANES ,AUTOANTIBODIES ,DENDRITIC cells ,FLOW cytometry ,GENES ,INTERFERONS ,LYMPHOCYTES ,NEPHRITIS ,PROTEINURIA ,RNA ,SYSTEMIC lupus erythematosus ,DISEASE progression ,DESCRIPTIVE statistics ,SEQUENCE analysis ,METABOLOMICS - Abstract
Objective: Type I interferons (IFNs) are critical in the development of systemic lupus erythematosus (SLE). Metabolic abnormalities cause dysregulation of multiple immune cells, but the metabolic regulation of type I IFN production is not well clarified in SLE. We undertook this study to define amino acid metabolism features in SLE and to explore the function of disease‐relevant metabolites in the control of plasmacytoid dendritic cell (pDC)–mediated type I IFN production and the progression of SLE. Methods: Metabolomic profiling of the serum from SLE patients and healthy controls was performed by mass spectrometry. The effects of SLE‐related metabolites on type I IFN production were explored in human and mouse pDCs. The reactive oxygen species (ROS) levels of pDCs from wild‐type and Ncf1−/− mice were measured by flow cytometry. Mechanisms were investigated by RNA sequencing and immunoblotting. In vivo effects of SLE‐relevant metabolites were systemically analyzed in B6.Cg‐Sle1NZM2410/Aeg Yaa/DcrJ mice. Results: Taurine was higher in the serum from SLE patients compared to healthy controls (P < 0.001) and rheumatoid arthritis patients (P < 0.001). Taurine content was positively correlated with disease activity and the expression of IFN signature genes. The addition of taurine facilitated IFN regulatory factor 7 phosphorylation and enhanced type I IFN production by reducing the ROS levels in pDCs in a neutrophil cytosolic factor 1–dependent manner. Taurine supplementation promoted expression of type I IFN–induced genes, activated lymphocytes, and increased autoantibodies and proteinuria, leading to more serious nephritis. Conclusion: Taurine metabolism is involved in the development of SLE by enhancing pDC‐mediated type I IFN production. Targeted inhibition of taurine or implementation of a taurine‐restricted diet has therapeutic potential in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated.
- Author
-
Wu, Chunmei, Fu, Qiong, Guo, Qiang, Chen, Sheng, Goswami, Shyamal, Sun, Shuhui, Li, Teng, Cao, Xingjian, Chu, Fuying, Chen, Zechuan, Liu, Mei, Liu, Yuanhua, Fu, Ting, Hao, Pei, Hao, Yi, Shen, Nan, Bao, Chunde, and Zhang, Xiaoming
- Subjects
CELL differentiation ,BIOCHEMISTRY ,FLOW cytometry ,RESEARCH ,LUPUS nephritis ,IMMUNOHISTOCHEMISTRY ,RESEARCH methodology ,PROGNOSIS ,EVALUATION research ,MEDICAL cooperation ,PHENOMENOLOGY ,CELLULAR signal transduction ,COMPARATIVE studies ,PSYCHOLOGICAL tests ,ENZYME-linked immunosorbent assay ,SYSTEMIC lupus erythematosus ,NEEDLE biopsy ,LONGITUDINAL method - Abstract
Objectives: A population of atypical memory B cells (AtMs) are greatly expanded in patients with active lupus, but their generation and pathophysiological roles are poorly defined. The aim of this study was to comprehensively characterise lupus AtMs with a purpose to identify therapeutic clues to target this B cell population in lupus.Methods: Peripheral B cell subsets were measured by flow cytometry. Sorting-purified B cell subsets were subject to RNA sequencing and functional studies. Plasma cytokines and secreted immunoglobulins were detected by Luminex or ELISA. In situ renal B cells were detected by multiplexed immunohistochemistry.Results: CD24-CD20hi AtMs were strongly increased in two Chinese cohorts of patients with treatment-naïve lupus. Gene expression profile indicated that B cell signalling and activation, lipid/saccharide metabolism and endocytosis pathways were abnormally upregulated in lupus AtMs. In addition, the mammalian target of rapamycin complex 1 (mTORC1) pathway was remarkably activated in lupus AtMs, and blocking mTORC1 signalling by rapamycin abolished the generation of T-bet+ B cells and terminal differentiation of lupus AtMs. Furthermore, lupus AtMs displayed a dysfunctional phenotype, underwent accelerated apoptosis, poorly co-stimulated T cells and produced proinflammatory cytokines. Interestingly, lupus AtMs were in a paradoxically differentiated status with markers pro and against terminal differentiation and enriched with antinucleosome reactivity. Finally, AtMs were accumulated in the kidneys of patients with lupus nephritis and associated with disease severity.Conclusions: These findings demonstrated that mTORC1-overactivated lupus AtMs are abnormally differentiated with metabolic and functional dysregulations. Inhibiting mTORC1 signalling might be an attractive option to target AtMs and to improve therapeutic effectiveness in patients with lupus. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
30. Identification of Renal Long Non-coding RNA RP11-2B6.2 as a Positive Regulator of Type I Interferon Signaling Pathway in Lupus Nephritis.
- Author
-
Liao, Zhuojun, Ye, Zhizhong, Xue, Zhixin, Wu, Lingling, Ouyang, Ye, Yao, Chao, Cui, Chaojie, Xu, Ning, Ma, Jianyang, Hou, Guojun, Wang, Jiehua, Meng, Yao, Yin, Zhihua, Liu, Ya, Qian, Jie, Zhang, Chunyan, Ding, Huihua, Guo, Qiang, Qu, Bo, and Shen, Nan
- Subjects
NON-coding RNA ,TYPE I interferons ,LUPUS nephritis ,SYSTEMIC lupus erythematosus ,ENZYME-linked immunosorbent assay - Abstract
Objective: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). Type I interferon (IFN-I) is associated with the pathogenesis of LN. Long non-coding RNAs (lncRNAs) have been implicated in the pathogenesis of SLE, however, the roles of lncRNAs in LN are still poorly understood. Here, we identified and investigated the function of LN-associated lncRNA RP11-2B6.2 in regulating IFN-I signaling pathway. Methods: RNA sequencing was used to analyze the expression of lncRNAs in kidney biopsies from LN patients and controls. Antisense oligonucleotides and CRISPRi system or overexpression plasmids and CRISPRa system were used to perform loss or gain of function experiments. In situ hybridization, imaging flow cytometry, dual-luciferase reporter assay, and ATAC sequencing were used to study the functions of lncRNA RP11-2B6.2. RT-qPCR, ELISA, and western blotting were done to detect RNA and protein levels of specific genes. Results: Elevated lncRNA RP11-2B6.2 was observed in kidney biopsies from LN patients and positively correlated with disease activity and IFN scores. Knockdown of lncRNA RP11-2B6.2 in renal cells inhibited the expression of IFN stimulated genes (ISGs), while overexpression of lncRNA RP11-2B6.2 enhanced ISG expression. Knockdown of LncRNA RP11-2B6.2 inhibited the phosphorylation of JAK1, TYK2, and STAT1 in IFN-I pathway, while promoted the chromatin accessibility and the transcription of SOCS1. Conclusion: The expression of lncRNAs is abnormal in the kidney of LN. LncRNA RP11-2B6.2 is a novel positive regulator of IFN-I pathway through epigenetic inhibition of SOCS1, which provides a new therapeutic target to alleviate over-activated IFN-I signaling in LN. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Association of Abnormal Elevations in IFIT3 With Overactive Cyclic GMP‐AMP Synthase/Stimulator of Interferon Genes Signaling in Human Systemic Lupus Erythematosus Monocytes.
- Author
-
Wang, Jiehua, Dai, Min, Cui, Yange, Hou, Guojun, Deng, Jun, Gao, Xin, Liao, Zhuojun, Liu, Ya, Meng, Yao, Wu, Lingling, Yao, Chao, Wang, Yan, Qian, Jie, Guo, Qiang, Ding, Huihua, Qu, Bo, and Shen, Nan
- Subjects
CELLULAR signal transduction ,CYTOKINES ,GENE expression ,INFLAMMATORY mediators ,INTERFERONS ,MONOCYTES ,PROTEIN kinases ,SYSTEMIC lupus erythematosus ,TRANSFERASES ,PRECIPITIN tests - Abstract
Objective: Increasing evidence indicates that the cyclic GMP‐AMP synthase/stimulator of interferon genes (cGAS/STING) signaling pathway has a critical pathogenic role in systemic lupus erythematosus (SLE). Expression levels of the interferon (IFN)–inducible gene IFIT3 are elevated in SLE patients. However, it is still not clear how IFIT3 contributes to the pathogenesis of SLE. This study was undertaken to investigate the activation of the cGAS/STING signaling pathway in human SLE monocytes, and to determine how elevated expression of IFIT3 could contribute to overactive cGAS/STING signaling in patients with SLE. Methods: Monocytes from SLE patients or healthy controls were examined for activity of the cGAS/STING signaling pathway and expression levels of IFIT3. Correlations between cGAS/STING signaling activity and SLE clinical features were analyzed. Gain‐ or loss‐of‐function experiments were used to determine the role of IFIT3 in cGAS/STING signaling. Coimmunoprecipitation assays were used to identify the interaction between IFIT3 and other proteins. Results: The cGAS/STING signaling pathway was found to have enhanced activity in monocytes from SLE patients compared to healthy controls, as indicated by the higher expression of IFNβ downstream. Levels of IFIT3 were significantly elevated in human SLE monocytes, and this was positively correlated with the activity of the cGAS/STING signaling pathway. In vitro, the expression of VACV70‐induced IFNβ was reduced by knockdown of IFIT3, whereas overexpression of IFIT3 produced an opposite effect. Finally, IFIT3 was found to interact with both STING and TANK‐binding kinase 1. Conclusion: These findings suggest that IFIT3 is one of the genes that contributes to the overactive cGAS/STING signaling pathway in human SLE monocytes. IFIT3 may therefore serve as a novel therapeutic target for blocking the production of type I IFN and other proinflammatory cytokines by the cGAS/STING signaling pathway in patients with SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. Identification of Cyclin-Dependent Kinase 1 as a Novel Regulator of Type I Interferon Signaling in Systemic Lupus Erythematosus.
- Author
-
Wu, Lingling, Qin, Yuting, Xia, Shiwei, Dai, Min, Han, Xiao, Wu, Yanfang, Zhang, Xiaoyan, Ma, Jianyang, Wang, Yan, Tang, Yuanjia, Liu, Zheng, Zhu, Wei, Jallal, Bahija, Yao, Yihong, Qu, Bo, and Shen, Nan
- Subjects
ANIMAL experimentation ,CELL culture ,CELLULAR signal transduction ,GENE expression ,INTERFERONS ,MICE ,PHOSPHORYLATION ,POLYMERASE chain reaction ,PROTEIN kinases ,RESEARCH funding ,STATISTICS ,SYSTEMIC lupus erythematosus ,T-test (Statistics) ,WESTERN immunoblotting ,DATA analysis ,DATA analysis software ,MICROARRAY technology ,DESCRIPTIVE statistics - Abstract
Objective Type I interferon (IFN) signaling is regarded as a central pathogenic pathway in systemic lupus erythematosus (SLE). Specific inhibition of this pathway is a core area for the development of new therapies for SLE. This study was undertaken to clarify the pathogenic mechanism involved and to identify new therapeutic targets, using a high-throughput screening platform to determine novel regulators that contribute to the overactivation of the type I IFN signaling pathway in SLE. Methods A high-throughput IFN-stimulated response element (ISRE)-luciferase assay was used to screen for candidate genes that regulate the IFN signaling pathway. Western blotting was used to confirm the regulatory function of CDK1. SYBR Green quantitative reverse transcriptase-polymerase chain reaction was used to detect the expression of individual IFN-stimulated genes (ISGs). The differential expression of CDK1 and ISGs in SLE patients and healthy controls was analyzed using RNA sequencing data and a microarray. Results The high-throughput ISRE-luciferase assay revealed that CDK1 enhanced type I IFN signaling. Consistent with this finding, CDK1 promoted the type I IFN-induced phosphorylation of STAT-1 and the up-regulated expression of ISGs. CDK1 expression was elevated in peripheral blood mononuclear cells (PBMCs) and kidney biopsy specimens from SLE patients and correlated positively with their IFN scores. A CDK1 inhibitor reduced the expression of ISGs in PBMCs from SLE patients and in renal cells from mice with lupus. Conclusion Our findings indicate that CDK1 is a positive regulator of the IFN signaling pathway. The overexpression of CDK1 might contribute to the abnormally amplified type I IFN signaling in SLE, and the inhibition of CDK1 could be used to down-regulate type I IFN signaling in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. In Vivo Therapeutic Success of MicroRNA-155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage.
- Author
-
Zhou, Shiyu, Wang, Yan, Meng, Yao, Xiao, Chunyuan, Liu, Zheng, Brohawn, Philip, Higgs, Brandon W., Jallal, Bahija, Jia, Qian, Qu, Bo, Huang, Xinfang, Tang, Yuanjia, Yao, Yihong, Harley, John B., and Shen, Nan
- Subjects
ANIMAL experimentation ,CELL culture ,CELLULAR signal transduction ,HEMORRHAGE ,LUNG diseases ,MICE ,POLYMERASE chain reaction ,RESEARCH funding ,RNA ,SYSTEMIC lupus erythematosus ,T-test (Statistics) ,DATA analysis software ,MICROARRAY technology ,GENE expression profiling ,DESCRIPTIVE statistics ,ONE-way analysis of variance ,IN vivo studies ,DISEASE complications - Abstract
Objective Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Pristane-treated B6 mice develop severe DAH within 2 weeks of treatment. MicroRNA-155 (miR-155) is a pleiotropic microRNA that plays a crucial role in the regulation of immune responses. Recent studies have revealed a pathogenic role of miR-155 in various autoimmune disorders. The purpose of this study was to examine the role of miR-155 in the development of DAH in pristane-induced lupus using miR-155-knockout (miR-155
−/− ) mice and miR-155 antagomir to silence miR-155. Methods DAH was induced by an intraperitoneal injection of 0.5 ml of pristane. MicroRNA-155 antagomir was administered intravenously to silence miR-155 expression. Lung tissues were collected for RNA extraction and were embedded in paraffin for sectioning. Gene expression profiling data were analyzed using Ingenuity Pathway Analysis. Real-time quantitative polymerase chain reaction analysis was used for single-gene validation. Luciferase reporter assay and argonaute 2 immunoprecipitation were performed for target validation. Results MicroRNA-155 expression was significantly increased during the development of DAH. Disease progression was reduced in miR-155−/− mice as well as by in vivo silencing of miR-155 using a miR-155 antagomir. MicroRNA-155 silencing dampened pristane-induced ectopic activation of multiple inflammatory pathways and reduced the expression of proinflammatory cytokines. Several negative regulators of NF-κB signaling were inhibited by pristane and were reactivated in miR-155−/− mice. In particular, the antiinflammatory factor peroxisome proliferator-activated receptor α was identified as a direct target of miR-155. Conclusion MicroRNA-155 promotes pristane-induced lung inflammation. It contributes to ectopic activation of NF-κB signaling pathways by targeting multiple negative regulators. MicroRNA-155 antagomir may be a promising therapeutic strategy for treating acute lung inflammation in lupus. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
34. Type I Interferon Inhibition of MicroRNA-146a Maturation Through Up-Regulation of Monocyte Chemotactic Protein-Induced Protein 1 in Systemic Lupus Erythematosus.
- Author
-
Qu, Bo, Cao, Jianchang, Zhang, Feifei, Cui, Huijuan, Teng, Jialin, Li, Jia, Liu, Zheng, Morehouse, Chris, Jallal, Bahija, Tang, Yuanjia, Guo, Qiang, Yao, Yihong, and Shen, Nan
- Subjects
ACADEMIC medical centers ,IMMUNOBLOTTING ,INTERFERONS ,POLYMERASE chain reaction ,RESEARCH funding ,STATISTICS ,SYSTEMIC lupus erythematosus ,DATA analysis ,REVERSE transcriptase polymerase chain reaction ,DATA analysis software ,MANN Whitney U Test - Abstract
Objective Systemic lupus erythematosus (SLE) is characterized by the uncontrolled production of inflammatory cytokines, among which type I interferon (IFN) is recognized as a crucial pathogenic factor. The expression of microRNA-146a (miR-146a) is reduced in the white blood cells of SLE patients and accounts for their overactivated inflammatory responses. However, the mechanism of the reduction of miR-146a is still not fully understood. This study was undertaken to test whether the key pathogenic cytokine, type I IFN, is responsible for the dysregulation of miR-146a in SLE. Methods Gene and protein expression was measured in all cells by reverse transcription-quantitative polymerase chain reaction, Northern blotting, or Western blotting. In THP-1 cells, expression of monocyte chemotactic protein-induced protein 1 (MCPIP-1) was knocked down with a lentivirus encoding a short hairpin RNA targeting MCPIP1. The cells were pretreated with type I IFN and assessed for gene expression levels of miR-146a. White blood cells from patients with SLE were analyzed for the expression of the IFN-inducible genes MCPIP1 and miR-146a, and the gene expression data were compared for correlation. Results Pretreatment of THP-1 cells with type I IFN attenuated the induction of miR-146a posttranscriptionally, by down-regulating the expression of pre-miR-146a but not pri-miR-146a or its original unspliced transcript. Expression of MCPIP-1, which was enhanced by type I IFN, was found to be responsible for the inhibition of miR-146a. In white blood cells from patients with SLE, MCPIP1 expression was elevated, and its expression correlated positively with the IFN score and negatively with the miR-146a transcript level. Conclusion Type I IFN inhibits the maturation of miR-146a through the up-regulation of MCPIP-1, and thus contributes to the uncontrolled inflammation and excessive inflammatory gene expression in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Overview of lupus nephritis management guidelines and perspective from Asia.
- Author
-
Mok, Chi Chiu, Yap, Desmond YH, Navarra, Sandra V, Liu, Zhi‐hong, Zhao, Ming‐hui, Lu, Liangjing, Takeuchi, Tsutomu, Avihingsanon, Yingyos, Yu, Xue‐qing, Lapid, Elizabeth A, Lugue‐Lizardo, Lenrore R, Sumethkul, Vasant, Shen, Nan, Chen, Shun‐le, and Chan, Tak Mao
- Subjects
LUPUS nephritis ,SYSTEMIC lupus erythematosus ,AUTOIMMUNE diseases ,KIDNEY diseases ,NEPHRITIS - Abstract
Lupus nephritis ( LN) is a common and important manifestation of systemic lupus erythematosus ( SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethnic groups. The management of LN has evolved considerably over the past three decades, based on observations from clinical studies that investigated different immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, mycophenolic acid, calcineurin inhibitors and novel biologic therapies. This is accompanied by improvements in both the short-term treatment response rate and long-term renal function preservation. Treatment guidelines for LN have recently been issued by rheumatology and nephrology communities in U.S.A. and Europe. In view of the racial difference in disease manifestation and response to therapy, and the substantial disease burden in Asia, a panel of 15 nephrologists and rheumatologists from different Asian regions with extensive experience in lupus nephritis - the Steering Group for the Asian Lupus Nephritis Network ( ALNN) - met and discussed the management of lupus nephritis in Asian patients. The group has also reviewed and deliberated on the recently published recommendations from other parts of the world. This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus.
- Author
-
Fan, Wei, Liang, Dong, Tang, Yuanjia, Qu, Bo, Cui, Huijuan, Luo, Xiaobing, Huang, Xinfang, Chen, Shunle, Higgs, Brandon W., Jallal, Bahija, Yao, Yihong, Harley, John B., and Shen, Nan
- Subjects
ENZYME-linked immunosorbent assay ,INTERLEUKINS ,POLYMERASE chain reaction ,RESEARCH funding ,RNA ,SYSTEMIC lupus erythematosus ,T cells ,T-test (Statistics) ,U-statistics ,WESTERN immunoblotting ,EQUIPMENT & supplies ,DATA analysis software - Abstract
Objective MicroRNAs (miRNAs) function to fine-tune the control of immune cell signaling. It is well established that there are abnormalities in the interleukin-2 (IL-2)-related signaling pathways in systemic lupus erythematosus (SLE). The miR-31 microRNA has been found to be markedly underexpressed in patients with SLE, and thus the present study was undertaken to investigate the role of miR-31 in IL-2 defects in lupus T cells. Methods Expression levels of miR-31 were quantitated using TaqMan miRNA assays. Transfection and stimulation of cultured cells followed by TaqMan quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, and reporter gene assays were conducted to determine the biologic function of miR-31. NF-AT nuclear translocation and expression were quantitatively measured using an ImageStream cytometer. Bioinformatics analysis, small interfering RNA (siRNA) knockdown, and Western blotting were performed to validate miR-31 targets and effects. Results The expression of miR-31 was significantly decreased in lupus T cells, and this was positively correlated with the expression of IL-2. Overexpression of miR-31 in T cells increased the production of IL-2 by altering NF-AT nuclear expression and IL2 promoter activity, while knockdown of endogenous miR-31 reduced IL-2 production. RhoA expression was directly repressed by miR-31 in T cells. Of note, siRNA-mediated knockdown of RhoA enhanced IL2 promoter activity and, consequently, up-regulated IL-2 production. RhoA expression was consistently up-regulated and negatively correlated with the levels of miR-31 in lupus T cells. Manipulation of miR-31 expression in lupus T cells restored the expression of IL-2 at both the messenger RNA and protein levels. Conclusion MicroRNA-31 is a novel enhancer of IL-2 production during T cell activation. Dysregulation of miR-31 and its target, RhoA, could be a novel molecular mechanism underlying the IL-2 deficiency in patients with SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
37. Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus.
- Author
-
Zhou, Xu-jie, Lu, Xiao-lan, Nath, Swapan K., Lv, Ji-cheng, Zhu, Sai-nan, Yang, Hai-zhen, Qin, Lian-xiang, Zhao, Ming-hui, Su, Yin, Shen, Nan, Li, Zhan-guo, and Zhang, Hong
- Subjects
SYSTEMIC lupus erythematosus ,CHI-squared test ,CONFIDENCE intervals ,EPIDEMIOLOGY ,GENES ,GENETIC polymorphisms ,MULTIVARIATE analysis ,RESEARCH funding ,STATISTICS ,LOGISTIC regression analysis ,GENOMICS ,DATA analysis ,CASE-control method ,DATA analysis software ,GENETICS - Abstract
Objective Although the number of convincingly established genetic associations with systemic lupus erythematosus (SLE) has increased sharply over the last few years, refinement of these associations is required, and their potential roles in gene-gene interactions need to be further investigated. Recent genome-wide association studies (GWAS) in SLE have produced renewed interest in B cell/T cell responses and the NF-κB signaling pathway. The aim of this study was to search for possible gene-gene interactions based on identified single-nucleotide polymorphisms (SNPs), in using an approach based on the role of signaling pathways. Methods The SNPs in BLK, TNFSF4, TRAF1, TNFAIP3, and REL were replicated in order to evaluate genetic associations with SLE. TaqMan genotyping was conducted in 804 Chinese patients with SLE and 722 matched control subjects. A multiple logistic regression model was used to estimate the multiplicative interaction effect of the SNPs, and additive interactions were analyzed by 2 × 2 factorial designs. Data from a previously published GWAS conducted by the International Consortium on the Genetics of Systemic Lupus Erythematosus were derived for comparison and validation. Results Single-marker analysis validated the association of BLK rs2736340 ( P = 4.25 × 10
−6 ) as well as TNFSF4 rs2205960 ( P = 2.82 × 10−5 ) and TNFAIP3 rs5029939 ( P = 1.92 × 10−3 ) with SLE susceptibility in Chinese. Multiplicative interaction analysis indicated that BLK had an interactive effect with TNFSF4 in Chinese patients with SLE ( P = 6.57 × 10−4 ). Additive interaction analysis revealed interactions between TRAF1 and TNFAIP3 in both Chinese ( P = 2.18 × 10−3 ) and Caucasians ( P = 2.86 × 10−4 ). In addition, multiple tendencies toward interactions were observed, and an additive effect was observed as the number of risk genotypes increased. Conclusion The results of this study provide evidence of the possible gene-gene interactions of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in SLE, which may represent a synergic effect of T cells and B cells through the NF-κB pathway in determining immunologic aberration. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
38. MicroRNA-146a Contributes to Abnormal Activation of the Type I Interferon Pathway in Human Lupus by Targeting the Key Signaling Proteins.
- Author
-
Tang, Yuanjia, Luo, Xiaobing, Cui, Huijuan, Ni, Xuming, Yuan, Min, Guo, Yanzhi, Huang, Xinfang, Zhou, Haibo, De Vries, Niek, Tak, Paul Peter, Chen, Shunle, and Shen, Nan
- Subjects
SYSTEMIC lupus erythematosus ,RNA ,INTERFERONS ,AUTOIMMUNE diseases ,GENE expression - Abstract
The article focuses on a study of MicroRNA-146a which contributes to abnormal activation of the type I interferon pathway in patients with systematic lupus erythematosus (SLE). SLE is a complex autoimmune disease that is characterized by chronic immune activation and multiple immunologic phenotypes. MicroRNA is identified as regulators that modulate target gene expression, which contributes to the pathogenesis of (SLE). Details on the biologic function of miR-146a are discussed.
- Published
- 2009
- Full Text
- View/download PDF
39. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α-producing antigen-presenting cells.
- Author
-
Yan, Bing, Ye, Shuang, Chen, Guangjie, Kuang, Miao, Shen, Nan, and Chen, Shunle
- Subjects
T cells ,SYSTEMIC lupus erythematosus ,INTERFERONS ,ANTIGENS ,HOMEOSTASIS ,PATIENTS - Abstract
The article investigates factors that can possibly impair the suppressive function of CD4+,CD25+ regulatory T cells among patients with untreated active systemic lupus erythematosus (SLE). According to the authors, CD4+,CD25+, FoxP3+ cells were higher in the peripheral blood of patients with SLE compared with normal subjects. They reveal that blockade of Treg cell-mediated suppression by interferon alpha-producing antigen-presenting cells may be a contributing factor to loss of tolerance to SLE.
- Published
- 2008
- Full Text
- View/download PDF
40. Could 2′5′-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study.
- Author
-
Ye, Shuang, Guo, Qiang, Tang, Jiang-ping, Yang, Cheng-de, Shen, Nan, and Chen, Shun-le
- Subjects
SYSTEMIC lupus erythematosus ,OLIGOADENYLATES ,INTERFERONS ,LUPUS erythematosus ,BIOMARKERS ,BACTERIAL diseases ,VIRAL antigens ,LOGISTIC regression analysis ,RHEUMATOLOGY ,PATIENTS - Abstract
2′5′-Oligoadenylate synthetase (OAS) was shown to be related to systemic lupus erythematosus (SLE) 20 years ago, and was rediscovered to be involved in type I interferon pathway in SLE by several microarray gene expression studies recently. The goal of this study was to investigate OAS isoform expressions in lupus patients, to evaluate whether they could become biomarkers to differentiate between disease flare and infection. Fifty-four SLE patients presented with fever or systemic inflammatory syndrome, or both, were enrolled. Gene expressions of OAS1, OAS2, and OASL were studied by using real time PCR in active SLE (SLEDAI ≥9, n=29) and in those complicated with infections ( n=25). The latter group was composed of 19 patients with invasive bacterial infections, and six patients with viral infections. C reactive protein (CRP) and other clinical parameters were also measured. Twenty-nine healthy individuals made up a normal control group. The mRNA expressions of OAS1, OAS2, and OASL were higher in patients with lupus flares than those with infections ( p<0.03), or normal controls ( p<0.001). SLE complicated with infections have higher OAS1 expression level ( P=0.002), lower OASL ( P=0.004), and equivalent OAS2 ( P=0.135), when compared with those of normal controls. OASL expression level was negatively correlated with infection in lupus by logistic regression analysis ( p=0.008). Area under the receiver operating characteristic curve for the prediction of infection was 0.92 ( p<0.0001) for OASL, and 0.77 ( p=0.007) for CRP. Therefore, our preliminary data suggest that the pattern of OAS isoform expressions, OASL in particular, may provide useful information in differentiating disease flares from certain infections in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
41. Reply.
- Author
-
Li, Jia, Bao, Chunde, and Shen, Nan
- Subjects
RNA ,LUPUS nephritis ,ARTERIOSCLEROSIS ,IMMUNE system ,SYSTEMIC lupus erythematosus ,DIAGNOSIS ,THERAPEUTICS - Abstract
A response by Jia Li and colleagues is presented to a letter to the editor about their article "Interferon-&alpha priming promotes lipid uptake and macrophage-derived foam cell formation: A novel link between interferon-&alpha and atherosclerosis in lupus" in the February 2011 issue.
- Published
- 2012
- Full Text
- View/download PDF
42. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus
- Author
-
Chan, Vera Sau-Fong, Nie, Yin-Jie, Shen, Nan, Yan, Sheng, Mok, Mo-Yin, and Lau, Chak-Sing
- Subjects
- *
SYSTEMIC lupus erythematosus , *DENDRITIC cells , *IMMUNOREGULATION , *MICRORNA , *INTERFERONS , *IMMUNOLOGICAL tolerance - Abstract
Abstract: Dendritic cells (DCs) constitute a heterogeneous population of professional antigen presenting cells which are the initiators and key regulators for both immunity and tolerance induction. The significance and impact of DC biology in contemporary immunology and medical research is heightened by the award of the 2011 Nobel Prize for Medicine and Physiology to Ralf Steinman for his discovery and subsequent work on the role of DC in adaptive immunity. As a central regulator of immune responses, DCs also play a pivotal role in the pathogenesis of chronic inflammatory autoimmune conditions such as systemic lupus erythematosus (SLE). In this review, we will focus on the respective role of the two major subsets of blood DC, namely myeloid (m)-DC and plasmacytoid (p)-DC, in SLE immunopathogenesis. Accumulating evidence has highlighted pDCs as the culprit for SLE pathogenesis, mainly through type-I interferon production. Latest findings in the field also decipher the mechanisms by which pDCs interact with neutrophils and platelets and contribute to SLE development. The recent surge of interest in studying microRNA regulation in SLE pathogenesis will also be discussed. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
43. Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus.
- Author
-
Zhang, Feifei, Wu, Lingling, Qian, Jie, Qu, Bo, Xia, Shiwei, La, Ting, Wu, Yanfang, Ma, Jianyang, Zeng, Jing, Guo, Qiang, Cui, Yong, Yang, Wanling, Huang, Jiaqi, Zhu, Wei, Yao, Yihong, Shen, Nan, and Tang, Yuanjia
- Subjects
- *
RIBOSOMAL DNA , *NON-coding RNA , *NUCLEIC acids , *SYNCRIP protein , *RNA world hypothesis - Abstract
Long noncoding RNAs (lncRNAs) have recently been identified to be tightly linked to diverse human diseases. However, our knowledge of Systemic Lupus Erythematosus (SLE)-related lncRNAs remains limited. In the present study we investigated the contribution of the lncRNA NEAT1 to the pathogenesis of SLE. Here, we found NEAT1 expression was abnormally increased in SLE patients and predominantly expressed in human monocytes. Additionally, NEAT1 expression was induced by LPS via p38 activation. Silencing NEAT1 significantly reduced the expression of a group of chemokines and cytokines, including IL-6, CXCL10, etc., which were induced by LPS continuously and in late stages. Furthermore, it was identified the involvement of NEAT1 in TLR4-mediated inflammatory process was through affecting the activation of the late MAPK signaling pathway. Importantly, there was a positive correlation between NEAT1 and clinical disease activity in SLE patients. In conclusion, the increased NEAT1 expression may be a potential contributor to the elevated production of a number of cytokines and chemokines in SLE patients. Our findings suggest lncRNA contributes to the pathogenesis of lupus and provides potentially novel target for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment.
- Author
-
Zhang, Jiali, Guo, Qianqian, Dai, Dai, Yu, Jian, Wang, Liting, Wu, Zhihua, Ding, Huihua, Shen, Nan, and Duan, Yourong
- Subjects
- *
CD28 antigen , *SYSTEMIC lupus erythematosus , *B cells , *REGULATORY T cells , *IMMUNOMODULATORS , *T cells , *NANOPARTICLES , *TREATMENT effectiveness - Abstract
Excessive CD4+ T helper (Th)–B-cell interactions and loss of Treg homeostasis are crucial to the pathogenesis of systemic lupus erythematosus (SLE). Targeting the SLE-specific upregulated costimulatory molecules ICOS or CD40L on Th can block Th–B reciprocal activation, but single costimulatory molecular blockade exhibited unsatisfactory therapeutic efficacy due to pathway redundancy. As ICOS and CD40L nonredundantly and cooperatively promote Th–B-cell reciprocal activation, simultaneously blocking ICOS and CD40L may achieve a synergistic effect. Moreover, inhibition of overactivated mTOR signaling by rapamycin (RAP) can promote Treg expansion while restraining autoreactive T-B-cell activation, which can work as an adjuvant to pair with costimulation blockade to restore immune homeostasis. However, systemic administration of multiple immune modulators is hindered by limited drug enrichment at the target site and increased systemic toxicity. Here, we rationally designed RAP-encapsulated ICOS/CD40L bispecific nanoparticles (NPs) to achieve multitarget therapy in a disease-specific manner. Through ex vivo cocultures of Th and B cells from SLE mice or patients and in vivo SLE mouse models, we demonstrated that RAP-encapsulated ICOS/CD40L bispecific NPs selectively target SLE Th cells and potently inhibit Th–B-cell reciprocal activation by targeting dual costimulatory pathways. In addition, the sustained release of RAP benefits from the precise targeting ability of bispecific NPs to further inhibit in situ Th–B cells while promote bystander Treg cells, which help to significantly alleviate SLE progression in both inducible and spontaneous lupus models with no obvious toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Systemic lupus erythematosus: A new autoimmune disorder in Kabuki syndrome.
- Author
-
Arsov, Todor, Sestan, Mario, Cekada, Nastasia, Frkovic, Marijan, Andrews, Dan, He, Yuke, Shen, Nan, Vinuesa, Carola G., and Jelusic, Marija
- Subjects
- *
SYSTEMIC lupus erythematosus , *PHOSPHOLIPID antibodies , *SYNDROMES , *RITUXIMAB , *DISEASES , *AUTOIMMUNE diseases - Abstract
We report a case of a 17-year-old Caucasian girl with syndromic features of clinically unrecognized Kabuki syndrome (KS), who developed systemic lupus erythematosus (SLE). Diagnosis of KS was established after whole exome sequencing (WES) and detection of de novo frameshift 1bp deletion in histone-lysine N-methyltransferase 2D gene (KMT2D). The pathogenic variant in exon 34 (c.8626delC: 55 reads C, 56 reads delC), has not been described previously and is predicted to truncate the protein (p.Gln2876Serfs*34) resulting in KMT2D loss of function. Notwithstanding that patients with KS have a substantial susceptibility to various autoimmune diseases, to the best of our knowledge this is the first report of an SLE and KS association. The exact relationship between the two conditions in our patient is difficult to determine with certainty, as a number of clinical features, including positive antiphospholipid antibodies, persistent hypogammaglobulinemia and the episode of convulsions may occur in both conditions, suggesting potential overlap of KS and SLE. The combination of a high susceptibility towards infections and an autoimmune disorder present a great challenge when trying to achieve the optimum therapy which will enable the patient to stay on the thin line of remission. This case report emphasizes the value of WES as a powerful tool for the diagnosis of rare disorders and/or unusual disease presentations of possible genetic cause. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. Structure and Degradation of Circular RNAs Regulate PKR Activation in Innate Immunity.
- Author
-
Liu, Chu-Xiao, Li, Xiang, Nan, Fang, Jiang, Shan, Gao, Xiang, Guo, Si-Kun, Xue, Wei, Cui, Yange, Dong, Kaige, Ding, Huihua, Qu, Bo, Zhou, Zhaocai, Shen, Nan, Yang, Li, and Chen, Ling-Ling
- Subjects
- *
CIRCULAR RNA , *PROTEIN kinases , *NATURAL immunity , *SYSTEMIC lupus erythematosus , *AUTOIMMUNE diseases - Abstract
Circular RNAs (circRNAs) produced from back-splicing of exons of pre-mRNAs are widely expressed, but current understanding of their functions is limited. These RNAs are stable in general and are thought to have unique structural conformations distinct from their linear RNA cognates. Here, we show that endogenous circRNAs tend to form 16–26 bp imperfect RNA duplexes and act as inhibitors of double-stranded RNA (dsRNA)-activated protein kinase (PKR) related to innate immunity. Upon poly(I:C) stimulation or viral infection, circRNAs are globally degraded by RNase L, a process required for PKR activation in early cellular innate immune responses. Augmented PKR phosphorylation and circRNA reduction are found in peripheral blood mononuclear cells (PBMCs) derived from patients with autoimmune disease systemic lupus erythematosus (SLE). Importantly, overexpression of the dsRNA-containing circRNA in PBMCs or T cells derived from SLE can alleviate the aberrant PKR activation cascade, thus providing a connection between circRNAs and SLE. • circRNAs are globally degraded by activated RNase L upon viral infection • Many circRNAs tend to form 16–26 bp duplexes and act as endogenous PKR inhibitors • The RNase L-mediated circRNA degradation is required for PKR activation • circRNA reduction and aberrant PKR activation are found in autoimmune disease SLE The unique structure of circRNAs allows them to bind and regulate the innate immune dsRNA receptor PKR, and misregulation of this process is found in patients with autoimmune disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.